1-6 of 6
Thomas Ly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Fabian Mueller, Krish Patel, Ran Reshef, Mohamad Cherry, Richard Nash, Ernesto Ayala, Jingmei Hsu, Jacques Azzi, Peter Vandenberghe, Roch Houot, Bastian von Tresckow, Giuseppina Stifano, Ashley Koegel, Susana Falcon, Burhan Chaudhry, Lisa Kelly, Jerill Thorpe, Alyse Frisbee, Sam Charab, Sharmila Das, Thomas Ly, Ken Ogasawara, Paolo Caimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 2088.
https://doi.org/10.1182/blood-2024-194525
Published: 2024
Journal Articles

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu-Waye Chu, Jae H. Park
Journal: Blood
Blood (2022) 140 (Supplement 1): 4577–4578.
https://doi.org/10.1182/blood-2022-167194
Published: 2022
Journal Articles

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Jesus G. Berdeja, Tara Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode P. Goodridge, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, John Byon, Rafat Abonour
Journal: Blood
Blood (2022) 140 (Supplement 1): 4586–4587.
https://doi.org/10.1182/blood-2022-166994
Published: 2022
Journal Articles

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Mark Juckett, Sham Mailankody, Alireza Eghtedar, Cara Bickers, Xingyue Zong, Lilly Wong, Thomas Ly, John Byon, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, Ravi Vij
Journal: Blood
Blood (2022) 140 (Supplement 1): 10327–10328.
https://doi.org/10.1182/blood-2022-166728
Published: 2022
Journal Articles

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Krish Patel, MD, Jean-Marie Michot, MD, Asher A. Chanan-Khan, MD, Gilles A. Salles, MD PhD, Guillaume Cartron, MD PhD, Frederic Peyrade, MD, Reda Bouabdallah, Erin G. Reid, MD MS, Sheeba K. Thomas, MD, William G. Wierda, MD PhD, David Liebowitz, MD, John M. Pagel, MD PhD DSc, Vincent Ribrag, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, Thomas Ly, PhD, Tycel J. Phillips, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4079.
https://doi.org/10.1182/blood-2019-128564
Published: 2019
Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 763.
https://doi.org/10.1182/blood-2018-99-119786
Published: 2018